Sutro Biopharma Inc (STRO) Stock AnalysisSTROStock AnalysisSutro Biopharma Inc

Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Sutro Biopharma Inc is a good buy right now due to its current price of $20.45, which is significantly lower than the analyst price targets of $50 and $48, suggesting a potential upside of 135% and 134% respectively. Additionally, the company has a strong cash position of $164.3 million, which is expected to fund operations into at least Q2 2028, providing a buffer for ongoing R&D and clinical trials. However, the main risk is the recent net loss of $38.5 million in Q2 2026, which indicates ongoing financial pressure.

4 analysts cover STRO: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 20.00.